Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet Oncol · 2026-10-09

In German women aged 50–70, tomosynthesis plus synthesised 2D mammography did not significantly reduce 24-month invasive interval breast cancer versus digital mammography (14·2 vs 18·6 per 10 000 screen-negative women; OR 0·76, 95% CI 0·55–1·06).

RCTn = 98,755
Weigel et al. Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial
Oncology · Lancet Oncol · 2026-10-01

Prespecified 10-year analysis of 810 women with high-risk breast cancer after mastectomy: locoregional recurrence was 12.0% with hypofractionated (43.5 Gy/15) vs 10.3% with conventional (50 Gy/25) radiotherapy (HR 1.19, 0.79-1.82); grade 3 late toxicity was rare in both.

RCTn = 810
Sun et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial
Oncology · Ann Oncol · 2026-08-24

OlympiA interim analysis (follow-up 6.1 years): in germline BRCA1/2 high-risk HER2-negative early breast cancer, 1 year of adjuvant olaparib vs placebo sustained invasive disease-free survival benefit (HR 0.65) and improved overall survival (HR 0.72; 6-year 87.5% vs 83.2%).

RCTn = 1,836
Garber et al. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.